The Readiness Standard & Your Role

The Trust Gap You're Being Asked to Close

Psychedelic and adjunct-therapy programs are growing faster than regulation can keep up with. Right now, when something goes wrong, there is usually no standardized documentation proving a patient was properly screened for cardiac, psychiatric, and drug-interaction risk, honestly informed of what is and isn't known, and supported before and after treatment. That undocumented gap is where liability, harm, and headlines land. Your job under the Readiness Standard is to close that gap for every patient in front of you — whether you're the intake clinician, the preparation guide, or the prescriber of record.

Phase 1 — Universal Readiness Screening Clinician sign-off Established

Before any of these medicines, a baseline assessment must be completed and reviewed by the treating team:

• General medical: history and exam, vitals, relevant labs (metabolic, hepatic, renal), pregnancy screen where applicable.
• Cardiovascular baseline: history, blood pressure, heart rate; several of these medicines raise BP/HR or affect cardiac rhythm, so modality annexes specify ECG/QTc where needed.
• Psychiatric: personal or family history of psychosis or bipolar disorder, plus a suicidality screen — the most consistent psychological contraindications across psychedelics.
• Medication and substance reconciliation: a complete list of prescriptions, OTC drugs, supplements, and substances, screened specifically for serotonergic drugs, QT-prolonging agents, and CYP interactions.
• Informed consent and education: confirmation the patient — and caregiver, where relevant — completed honest education and understands benefits, risks, and unknowns.

Phase 2 — Universal Preparation Plausible

• Low-risk terrain optimization (sleep, hydration, nutrition, reduced alcohol/stimulants, management of inflammatory and vascular risk factors) — generally beneficial on its own merits regardless of any treatment effect.
• Medication adjustments are prescriber-only. Some regimens require a supervised taper (for example, serotonergic medications before MDMA or ibogaine). This decision belongs solely to the treating prescriber — never to you as an educator or coach, and never to a supplement protocol.
• Toxicant handling is test-first: assess before acting, and address a genuine documented burden conservatively, well ahead of the treatment date.
• Psychological preparation: intention-setting, grounding, and a support circle for the patient; a prepared caregiver.

Phase 3 — Clear-to-Treat Handoff and the Contraindication Framework Clinician sign-off

The handoff is a documentation packet the treating clinician reviews and signs: screening results, medication reconciliation, contraindication review, completed consent, completed education, and the applicable modality safety annex. The go/no-go decision belongs to the treating clinician alone — the standard documents readiness, it does not clear anyone.

• Domains that must be flagged for the treating physician to set exact thresholds and decisions: significant or uncontrolled cardiovascular disease or arrhythmia.
• Uncorrected electrolyte abnormalities (potassium, magnesium, calcium).
• Significant hepatic or renal impairment.
• Active psychosis or unmanaged bipolar disorder; acute suicidality.
• Pregnancy, and contraindicated concurrent medications that cannot be safely managed.

What "Certified" Actually Means — Your Scope

Certification under this standard works like a diving certification, not a safety claim about the ocean: it never asserts that any psychedelic or adjunct therapy is safe or effective. It attests that a program, provider, or patient record meets a defined bar for screening, honest disclosure, and documented process. As a Certified Provider, you are being trained and assessed on readiness screening, informed consent, and crisis response — a portable credential, not a license to make medical-clearance decisions you don't otherwise hold.

• If you are the treating or prescribing clinician, the standard organizes and documents your process — it does not replace your clinical judgment or your license's scope.
• If you are not the prescriber (intake, preparation coaching, integration support), your job is to gather, document, and escalate. The treating clinician decides.
• The certification is never medical clearance, never an FDA or medical-board accreditation, and never a guarantee that harm can't happen.

The Honesty Compact

Every claim you make to a patient or caregiver gets graded the same way this course grades claims to you: Established, Plausible, or Hypothesis — never "proven safe," never "will help you." If you don't know, say you don't know; if it's a hope rather than a finding, call it a hope. The standard's own outcomes claim — that structured preparation improves treatment results — is tagged Hypothesis, not fact, and is exactly what the standard's registry exists to test honestly. Model that same discipline in every patient conversation.

Conflicts of Interest: Know Your Own

The standard is built on a firewall: certification is never contingent on a program or patient buying any commercial product, and the standards/certification function is kept structurally separate from any commercial arm. That protects the standard's credibility — a standard that profits from what it certifies is worthless. You carry the same obligation individually.

• Disclose in writing, before you screen or consent anyone, any financial relationship you or your program have with a product, supplement line, referral arrangement, or the treatment being prepared for.
• Keep that disclosure separate from the clinical recommendation itself — a patient should never have to guess whether your advice is shaped by what you sell.
• If a product or supplement recommendation and a screening/consent decision touch the same patient, document that the two were made independently.

Clinical Pharmacology You Need to Know Cold

These are Established findings you should be able to state without notes, because they change what you screen for and what you escalate.

• Ibogaine (Schedule I): blocks the cardiac hERG potassium channel, prolongs the QT interval, and can cause fatal ventricular arrhythmia — including Torsades de Pointes — at therapeutic doses, and case reports document this occurring in individuals with no pre-existing cardiac disease. Established
• Ibogaine is metabolized primarily by CYP2D6 to its active metabolite noribogaine. A controlled pharmacokinetic study found active-moiety exposure roughly two-fold higher when CYP2D6 activity was pharmacologically reduced — the basis for genotyping and dose-reduction in poor metabolizers, and for treating CYP2D6-inhibiting medications (some SSRIs) as a same-day escalation flag. Established
• MDMA (Schedule I, not FDA-approved): strongly serotonergic, creating real serotonin syndrome risk when combined with SSRIs, SNRIs, or MAOIs; also causes hyperthermia and hyponatremia (from over-hydration), and raises blood pressure and heart rate. In 2024 the FDA declined to approve MDMA-assisted therapy for PTSD, citing trial-design problems and incomplete cardiac (QT) and abuse-liability safety data — a reminder that "established mechanism" and "adequately characterized in trials" are not the same thing. Established
• Ketamine (Schedule III, legal off-label use) and esketamine (FDA-approved nasal spray for treatment-resistant depression) are related but not interchangeable regulatory categories. Repeated or heavy ketamine use is linked to ulcerative cystitis and, in documented cases, hydronephrosis and acute renal failure — bladder and renal function belong in any repeated-course monitoring plan, not just a one-time baseline. Established
• Psilocybin, LSD, and DMT (Schedule I): psychiatric screening is the consistent, non-negotiable safety layer — meta-analytic data shows serious adverse events are rare in monitored research settings but concentrate heavily in participants with pre-existing psychotic or bipolar-spectrum conditions. Established (psychiatric screening) · Plausible (favorable medical safety profile specifically in controlled, monitored settings)

Provider Certification Checklist

• I can state, without notes, what my certification does and doesn't attest to — and I never imply it means a substance is safe or effective.
• I know whether I am, or am not, the treating clinician for each patient in front of me, and I act within that boundary.
• I speak to patients and caregivers in fact / hypothesis / unknown language, every time.
• I have disclosed, in writing, any financial relationship I or my program hold with a product or treatment being discussed.
• I can name the cardiac (hERG/QT), CYP2D6, and serotonin-syndrome red flags for the modalities I work with, and I know exactly who I escalate to.
• I document readiness — I do not clear patients unless clearing patients is independently within my own licensed scope.